Ulinastatin
Based on 4 publication(s) in Google Scholar
Ulinastatin (Uristatin) is a trypsin and serine protease inhibitor. Ulinastatin is the main protein binding inhibitor of various trypsin, chymotrypsin, and various pancreatic proteases. Ulinastatin shows neuroprotective, anti-inflammatory, anti-apoptotic, anti-oxidant effects.
For research use only. We do not sell to patients.
- CAS No.: 80449-31-6
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Ulinastatin
More-
Histological Imaging/Staining
-
IF
-
RT-PCR
-
WB
-
IHC
Biological Activity
Ulinastatin (500-5000 U; 24 hours) markedly attenuates TLR4 expression and NF-κB activation in LPS-stimulated BEAS-2B cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human lung epithelial BEAS-2B cells
-
Concentration:500 U, 2500 U, 5000 U
-
Incubation Time:24 hours
-
Result:Markedly attenuated TLR4 expression and NF-κB activation in LPS-stimulated BEAS-2B cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice (8-10 weeks old, 18-22 g)[1]
-
Dosage:10000 U/kg
-
Administration:i.v.; twice (1 h before and 6 h after LPS treatment)
-
Result:Significantly protected animals from LPS-induced ALI.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 80449-31-6
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Ulinastatin]
-
Synonyms
Uristatin
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharmacol Sin
A sinomenine derivative protects life-threatening inflammatory injuries via covalently binding to a novel allosteric inhibition site of IRF3. [Abstract]2026 Jan 16. PMID: 41545756 -
Phytomedicine
Qingjie Huagong decoction inhibits pancreatic acinar cell pyroptosis by regulating circHipk3/miR-193a-5p/NLRP3 pathway. [Abstract]2024 Apr:126:155265. PMID: 38422649 -
Eur J Pharmacol
Octreotide attenuates experimental severe acute pancreatitis through inhibiting pyroptosis and modulating intestinal homeostasis. [Abstract]2025 Feb 6:177314. PMID: 39922420 -
J Ovarian Res
2025 Sep 29;18(1):207. PMID: 41024007
Ulinastatin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Sep 29;18(1):207. [Abstract]
H&E staining results of rat ovaries treated with cisplatin on days 14 and 35 treated with Ulinastatin (15, 30 mg/kg, i.p.).
Ulinastatin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Sep 29;18(1):207. [Abstract]
TUNEL staining of ovarian tissues of rats treated with Ulinastatin (15, 30 mg/kg, i.p.).
Ulinastatin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Sep 29;18(1):207. [Abstract]
qPCR results of Keap1, Nrf2, TGFβ-1, FN, Cleaved-caspase3, BAX, and Bcl2 in cells of each group after treatment with Ulinastatin (15, 30 mg/kg, i.p.) on day 14 using Cisplatin.
Ulinastatin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Sep 29;18(1):207. [Abstract]
WB results of Keap1, Nrf2, TGFβ-1, FN, Cleaved-caspase3, BAX, and Bcl2 in cells of each group after treatment with Ulinastatin (15, 30 mg/kg, i.p.) on days 14 and 35 using Cisplatin.
Ulinastatin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Sep 29;18(1):207. [Abstract]
Immunohistochemical results of Keap1, Nrf2, TGFβ-1, and FN in cells of each group after treatment with Ulinastatin (15, 30 mg/kg, i.p.) on day 14 of Cisplatin use.
Solvent & Solubility
H2O : 10 mg/mL (Need ultrasonic)
DMSO : 1 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shangping Fang, et al. Research progress of ulinastatin in the treatment of liver diseases. Int J Clin Exp Pathol. 2020 Nov 1;13(11):2720-2726. [Content Brief]
[2]. Cao C, et al. Ulinastatin Protects Against LPS-Induced Acute Lung Injury By Attenuating TLR4/NF-κB Pathway Activation and Reducing Inflammatory Mediators. Shock. 2018 Nov;50(5):595-605. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)